CFGF401
Total Payments
$246,501
Transactions
12
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $94,333 | 4 | 0 |
| 2018 | $62,030 | 4 | 0 |
| 2017 | $90,137 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $246,501 | 12 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF ORAL FGF401 IN ADULT PATIENTS WITH HEPATOCELLULAR CARCINOMA OR SOLID MALIGNANCIES CHARACTERIZED BY POSITIVE FGFR4 AND KLB EXPRESSION | Novartis Pharmaceuticals Corporation | $246,501 | 0 |
Top Doctors Receiving Payments for CFGF401
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $246,501 | 12 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $246,501
Product Information
- Type Drug
- Total Payments $246,501
- Total Doctors 0
- Transactions 12
About CFGF401
CFGF401 is a drug associated with $246,501 in payments to 0 healthcare providers, recorded across 12 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2019. In 2019, $94,333 was paid across 4 transactions to 0 doctors.
The most common payment nature for CFGF401 is "Unspecified" ($246,501, 100.0% of total).
CFGF401 is associated with 1 research study, including "A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF ORAL FGF401 IN ADULT PATIENTS WITH HEPATOCELLULAR CARCINOMA OR SOLID MALIGNANCIES CHARACTERIZED BY POSITIVE FGFR4 AND KLB EXPRESSION" ($246,501).